I have raised this previously. Could anyone advise a link to somewhere where I can confirm that applications for Gattex to general cancer patients are definitely off the table? I cannot find anything anywhere. I have looked so I am not wasting your time and I am a patent lawyer with a background in biotech!
Given the change in the market projections in the last CC espectially regarding Natpara, if there is any possibility of those Gattex applications going ahead, it would change the PPS and/or takeover outcomes dramatically. .
NPSP is going to be a game changer for many of us, so any help would be really appreciated.
I could see mainly one indication in cancer patients and that would be post BMT patients with severe gut GvHD refractory to everything. The problem in cancer patients especially in the GI cancer patients who would stand to benefit the most is what the company itself reports:
"pharmacologic activity and findings in animals, GATTEX has the potential to cause hyperplastic changes including neoplasia. In patients at increased risk for malignancy, the clinical decision to use GATTEX should be considered only if the benefits outweigh the risks. In patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic), GATTEX therapy should be discontinued. In patients with active non-gastrointestinal malignancy, the clinical decision to continue GATTEX should be made based on risk-benefit considerations."
I think this limits their application in cancer patients. In addition, it takes weeks for the benefits to be realized and most cancer patients who have malabsorption may not benefit in time or have their issues resolved in other ways.